TABLE 5.

Risk of depression and anxiety associated with duration of GLP1-RA use.

Variables	Any depression or anxiety (n = 1,014)			cHR	(95% CI)	aHR	(95% CI)
	Event	PY	IR
non-use GLP1-RA	857	91,546	9.36	1.00	(Reference)	1.00	(Reference)
GLP1-RA drug days
30–90 days	72	7,542	9.55	1.01	(0.79, 1.29)	1.22	(0.96, 1.56)
91–180 days	47	7,380	6.37	0.68	(0.5, 0.91)**	0.76	(0.57, 1.02)
>180	38	8,169	4.65	0.49	(0.35, 0.67)***	0.5	(0.36, 0.69)***

Variables	Anxiety (n = 772)			cHR	(95% CI)	aHR	(95% CI)
	Event	PY	IR
non-use GLP1-RA	656	91,838	7.14	1.00	(Reference)	1.00	(Reference)
GLP1-RA drug days
30–90 days	56	7,570	7.40	1.03	(0.79, 1.36)	1.3	(0.98, 1.71)
91–180 days	36	7,403	4.86	0.68	(0.48, 0.95)*	0.77	(0.55, 1.07)
>180 days	24	8,185	2.93	0.4	(0.27, 0.61)***	0.41	(0.27, 0.61)***

Variables	Depression (n = 376)			cHR	(95% CI)	aHR	(95% CI)
	Event	PY	IR
non-use GLP1-RA	308	92,594	3.33	1.00	(Reference)	1.00	(Reference)
GLP1-RA drug days
30–90 days	32	7,629	4.19	1.24	(0.86, 1.78)	1.4	(0.97, 2.03)
91–180 days	18	7,460	2.41	0.71	(0.44, 1.15)	0.79	(0.49, 1.27)
>180 days	18	8,215	2.19	0.63	(0.39, 1.02)	0.68	(0.42, 1.10)

PY, person-years; IR, incidence rate, per 1,000 person-years; HR, hazard ratio; CI, confidence interval.

Demographic factors include age, gender, urbanization level and enrollee category1:4 propensity score matching.